On October 27, 2015 – AbCheck s.r.o ., a technology company focusing on the discovery and optimization of high – quality human antibodies, reported the achievement of a first milestone in its strategic partnership with Pierre Fabre Pharmaceuticals of Castres, France (Press release, AbCheck, OCT 27, 2015, View Source [SID:SID1234515613]). The milestone represents confirmation of in vivo activity for at least one antibody discovered by AbCheck under the collaboration agreement and triggers an undisclosed miles tone payment from Pierre Fabre.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AbCheck , a wholly owned subsidiary of Affimed, Heidelberg, Germany, recognized throughout the US and Europe for its expertise in discovering and optimizing human antibodies and Pierre Fabre, France’s third – largest pharmaceutical company with a long – standing commi tment to oncology and immunology, entered into a development collaboration in 2014. This collaboration was expanded into a strategic partnership in June 2015. Under the ongoing agreement, AbCheck uses its proprietary human antibody discovery platform and o ptimization technologies to deliver antibodies against Pierre Fabre’s targets.

"Reaching this first milestone for Pierre Fabre proves the effectiveness of our technology platforms for the efficient discovery of high – quality antibodies," said Dr. Volker La ng, Managing Director of AbCheck. "We have recently added a novel mass humanization technology to our established technologies, which include the proprietary AbSieve and AbAccel platforms."